Pharmaceutical Supply Chain Risk Assessment Act of 2023

Bill 118 s 1961, also known as the Pharmaceutical Supply Chain Risk Assessment Act of 2023, is a piece of legislation currently being considered by the US Congress. The main purpose of this bill is to address the potential risks and vulnerabilities in the pharmaceutical supply chain in order to ensure the safety and security of medications for American consumers.

The bill requires pharmaceutical manufacturers, distributors, and other entities involved in the supply chain to conduct a comprehensive risk assessment of their operations. This assessment will help identify potential threats to the supply chain, such as counterfeit drugs, theft, or natural disasters, and develop strategies to mitigate these risks.

Additionally, the bill mandates that these entities establish protocols for reporting and responding to supply chain disruptions in a timely manner. This will help ensure that any issues that arise can be addressed quickly and effectively to minimize the impact on patients. Furthermore, the bill includes provisions for increased transparency and accountability in the pharmaceutical supply chain. This includes requirements for tracking and tracing medications throughout the supply chain to prevent diversion and ensure authenticity. Overall, the Pharmaceutical Supply Chain Risk Assessment Act of 2023 aims to strengthen the security and reliability of the pharmaceutical supply chain in the United States. By requiring risk assessments, establishing reporting protocols, and increasing transparency, this bill seeks to protect consumers and ensure the safe and timely delivery of medications.